NASDAQ:FBLG FibroBiologics (FBLG) Stock Price, News & Analysis $0.60 +0.08 (+14.55%) Closing price 09/24/2025 04:00 PM EasternExtended Trading$0.60 0.00 (-0.40%) As of 06:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About FibroBiologics Stock (NASDAQ:FBLG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get FibroBiologics alerts:Sign Up Key Stats Today's Range$0.52▼$0.6150-Day Range$0.53▼$0.6952-Week Range$0.51▼$3.89Volume1.49 million shsAverage Volume407,249 shsMarket Capitalization$25.23 millionP/E RatioN/ADividend YieldN/APrice Target$12.67Consensus RatingBuy Company Overview FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas. Read More FibroBiologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreFBLG MarketRank™: FibroBiologics scored higher than 53% of companies evaluated by MarketBeat, and ranked 431st out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingBuy Consensus RatingFibroBiologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Upside PotentialFibroBiologics has a consensus price target of $12.67, representing about 2,002.7% upside from its current price of $0.60.Amount of Analyst CoverageFibroBiologics has only been the subject of 2 research reports in the past 90 days.Read more about FibroBiologics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for FibroBiologics are expected to grow in the coming year, from ($0.53) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of FibroBiologics is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of FibroBiologics is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFibroBiologics has a P/B Ratio of 7.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about FibroBiologics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.06% of the float of FibroBiologics has been sold short.Short Interest Ratio / Days to CoverFibroBiologics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in FibroBiologics has recently decreased by 16.58%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFibroBiologics does not currently pay a dividend.Dividend GrowthFibroBiologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.06% of the float of FibroBiologics has been sold short.Short Interest Ratio / Days to CoverFibroBiologics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in FibroBiologics has recently decreased by 16.58%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for FibroBiologics this week, compared to 2 articles on an average week.Search Interest25 people have searched for FBLG on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added FibroBiologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, FibroBiologics insiders have not sold or bought any company stock.Percentage Held by Insiders20.00% of the stock of FibroBiologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about FibroBiologics' insider trading history. Receive FBLG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroBiologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FBLG Stock News HeadlinesFibroBiologics to Present at 2025 Cell & Gene Meeting on the MesaSeptember 23 at 8:30 AM | globenewswire.comFibroBiologics' (FBLG) "Buy" Rating Reiterated at HC WainwrightSeptember 15, 2025 | americanbankingnews.com7 Stocks Before the Year Slams ShutThe clock is ticking. 2025’s final quarter could be the last big rally before the reset of 2026. We’ve zeroed in on 7 stocks primed to surge before year-end. This isn’t noise, it’s your shot to finish 2025 ahead of the crowd. But wait too long, and Wall Street takes it first. | StockEarnings (Ad)FibroBiologics publishes opinion editorial on stem cell therapiesSeptember 12, 2025 | msn.comFibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell TherapiesSeptember 12, 2025 | globenewswire.comFibroBiologics announces IND-enabling updates from psoriasis research programSeptember 11, 2025 | msn.comFibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis TreatmentSeptember 11, 2025 | globenewswire.comFBLG: Advancing Bone Marrow Organoid Platform for Cancer and Immune-Related Therapies…September 10, 2025 | finance.yahoo.comSee More Headlines FBLG Stock Analysis - Frequently Asked Questions How have FBLG shares performed this year? FibroBiologics' stock was trading at $2.00 at the beginning of the year. Since then, FBLG stock has decreased by 69.9% and is now trading at $0.6024. How were FibroBiologics' earnings last quarter? FibroBiologics Inc. (NASDAQ:FBLG) issued its earnings results on Thursday, July, 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.01. When did FibroBiologics IPO? FibroBiologics (FBLG) raised $144 million in an IPO on Wednesday, January 31st 2024. The company issued 4,806,226 shares at a price of $30.00 per share. Who are FibroBiologics' major shareholders? FibroBiologics' top institutional investors include Cascade Financial Partners LLC (0.69%), Geode Capital Management LLC (0.69%), Cerity Partners LLC (0.31%) and Jane Street Group LLC (0.23%). View institutional ownership trends. How do I buy shares of FibroBiologics? Shares of FBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of FibroBiologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that FibroBiologics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Netflix (NFLX). Company Calendar Last Earnings7/31/2025Today9/24/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FBLG Previous SymbolNASDAQ:FBLG CIK1958777 Webwww.fibrobiologics.com Phone281-671-5150FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for FibroBiologics$12.67 High Price Target$16.00 Low Price Target$10.00 Potential Upside/Downside+2,002.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-710.25% Return on Assets-118.02% Debt Debt-to-Equity RatioN/A Current Ratio0.93 Quick Ratio0.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book7.53Miscellaneous Outstanding Shares41,890,000Free Float33,511,000Market Cap$25.23 million OptionableN/A Beta-0.73 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:FBLG) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroBiologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroBiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.